Your SlideShare is downloading. ×
Pipeline Insight: Alzheimer's Disease - The ultimate high-risk, high-reward therapy market
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Pipeline Insight: Alzheimer's Disease - The ultimate high-risk, high-reward therapy market

117

Published on

IntroductionDriven by the launch of disease modifying treatments and an expanding patient population, the Alzheimer's disease market will more than double over the next 10 years. Late-stage pipeline …

IntroductionDriven by the launch of disease modifying treatments and an expanding patient population, the Alzheimer's disease market will more than double over the next 10 years. Late-stage pipeline products such as Pfizer/Medivation's Dimebon (latrepirdine) and Johnson & Johnson/Wyeth's bapineuzumab hold blockbuster potential. However, the risk of clinical trial failure remains high in this indication.Scope*Forecasts to 2018 for Alzheimer's disease, total dementia, and mild cognitive impairment for novel disease-modifying agents in the seven major markets*Forecasts to 2018 of current brand reformulations targeting the symptomatic relief market.*Provides a global Alzheimer's disease market snapshot, and analysis of patient population growth trends in the seven major markets and BRIC nations.*Discusses the requirement for biomarker development and targeting patients earlier in the course of their disease.HighlightsWith impressive Phase II data, a strong marketing partner, and broad target population, Datamonitor forecasts multi-billion dollar sales for Pfizer and Medivation's Dimebon (latrepirdine) over the forecast period 20092018.Driven by prescribing in non-ApoE4 allele patients, Datamonitor forecasts lucrative sales for Johnson & Johnson/Wyeth's bapineuzumab. Off-label prescribing for pre-dementia/prodromal Alzheimer's disease type mild cognitive impairment patients will add significant revenue towards the end of the 10-year outlook.It is unlikely that a treatment will be developed which completely halts, or reverse, the cognitive decline observed in Alzheimer's disease over the 10 year time horizon. Therefore, a symptomatic market will remain active in this disease over the forecast period.Reasons to Purchase*Quantify the current size of the global Alzheimer's disease market.*Appreciate the demographic changes leading to anticipated growth in the Alzheimer's disease market.*Quantify the market to 2018 in the US, Japan, and five key European markets while identifying the major drivers, resistors, and risks.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
117
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Pipeline Insight: Alzheimers Disease - The ultimate high-risk,high-reward therapy marketPublished on August 2009 Report SummaryIntroductionDriven by the launch of disease modifying treatments and an expanding patient population, the Alzheimers disease market will morethan double over the next 10 years. Late-stage pipeline products such as Pfizer/Medivations Dimebon (latrepirdine) and Johnson &Johnson/Wyeths bapineuzumab hold blockbuster potential. However, the risk of clinical trial failure remains high in this indication.Scope*Forecasts to 2018 for Alzheimers disease, total dementia, and mild cognitive impairment for novel disease-modifying agents in theseven major markets*Forecasts to 2018 of current brand reformulations targeting the symptomatic relief market.*Provides a global Alzheimers disease market snapshot, and analysis of patient population growth trends in the seven major marketsand BRIC nations.*Discusses the requirement for biomarker development and targeting patients earlier in the course of their disease.HighlightsWith impressive Phase II data, a strong marketing partner, and broad target population, Datamonitor forecasts multi-billion dollarsales for Pfizer and Medivations Dimebon (latrepirdine) over the forecast period 20092018.Driven by prescribing in non-ApoE4 allele patients, Datamonitor forecasts lucrative sales for Johnson & Johnson/Wyethsbapineuzumab. Off-label prescribing for pre-dementia/prodromal Alzheimers disease type mild cognitive impairment patients will addsignificant revenue towards the end of the 10-year outlook.It is unlikely that a treatment will be developed which completely halts, or reverse, the cognitive decline observed in Alzheimersdisease over the 10 year time horizon. Therefore, a symptomatic market will remain active in this disease over the forecast period.Reasons to Purchase*Quantify the current size of the global Alzheimers disease market.*Appreciate the demographic changes leading to anticipated growth in the Alzheimers disease market.*Quantify the market to 2018 in the US, Japan, and five key European markets while identifying the major drivers, resistors, and risks.Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 1/13
  • 2. Find Industry reports, Company profilesReportLinker and Market Statistics Table of ContentOverview 1Catalyst 1Summary 1ABOUT DATAMONITOR HEALTHCARE 2About the Central Nervous System pharmaceutical analysis team 2Executive Summary 3Strategic scoping and focus 3Datamonitor insight into the Alzheimers disease market 3Related reports 5Table of Contents 61. Pipeline Overview and Dynamics 7Key findings 7Pipeline overview 8Interest remains strong in this high risk/high reward indication 8Clinical trial attrition is very high in Alzheimers disease 8Movement towards more targeted drugs 8Trends in the current pipeline 10Comparative forecasts - Pfizers Dimebon best positioned for commercial success 11Datamonitor Pipeline Assessment Summary - disease modification enhances clinical attractiveness 12Key companies involved in the Alzheimers disease pipeline 13Big Pharma companies partner their way into Alzheimers pipeline 13Elan Pharmaceuticals 14Pfizer and Wyeth 15Key R&D company strategies 16Diverse drug discovery approaches 16Beta-amyloid is the primary drug discovery target 16Secondary indications are possible but not yet under development 172. Alzheimers Disease: Market Potential 18Key findings 18Definition 19Overview 19World Health Organization classification and scope 211) Alzheimers disease-specific sales 212) Other dementia-specific sales 223) Mild cognitive impairment 22Syndrome description and patient segmentation 22Dementia 22Alzheimers disease 23Mild cognitive impairment 24Mild cognitive impairment subtypes 25Mild cognitive impairment subtypes and their links to Alzheimers disease 26Alzheimers disease is the most frequent outcome of mild cognitive impairment 27Epidemiology 28Seven major markets 28Alzheimers disease prevalence and patient population 28Alzheimers disease prevalence estimates methodology 30Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 2/13
  • 3. Find Industry reports, Company profilesReportLinker and Market StatisticsAlternative US patient population estimates 31Patient population projections across the seven major markets 32Rest of the world 36Lower current prevalence rates than in more developed markets 36Projected demographic changes drive growth in Alzheimers disease population 37Diagnosis rate of cognitive disorders 40Dementia (including Alzheimers disease) 40Mild cognitive impairment 42Current treatment options 42Brand dynamics and key past events 42Drug profiles 42Historical sales and off-label prescribing 43Current gold standard and comparator therapies 47Gold standard or comparator therapy: Aricept 47Leading Alzheimers disease therapy 48Superior efficacy did not drive the success of Aricept 50Current market overview 53Global Alzheimers disease market 53Alzheimers disease-specific sales across the seven major markets 54Unmet need in Alzheimers disease 56Disease modifying/slowing treatments 56Early treatment with disease slowing drugs should produce a better outcome 58Improved symptomatic efficacy 59Better diagnostic tools 60Current diagnostic techniques are subjective 61Better diagnostics required for early treatment and a better outcome 61Better understanding of the disease etiology 62Current level of attainment vs. target product profile 62Different efficacy expectations for symptomatic or disease modifying treatments 63Safety and tolerability 63Formulation/dosing 63Target population 64Price 643. R&D Approach 66Key findings 66Clinical trial design in Alzheimers disease 67What constitutes disease modification 68Determination of disease modification 68Clinical trial endpoints 71Alzheimers Disease Assessment Scale-cognitive portion (ADAS-Cog) 71Alzheimers Disease Cooperative Study: Activities of Daily Living (ADCS-ADL) 71Mini-Mental Status Exam 72Clinicians Interview-Based Impression of Change 72Neuropsychiatric Inventory 72Utilization in Dementia 72Neuropsychological Test Battery 73Severe Impairment Battery 73Clinical Dementia Rating 734. Pipeline Analysis & Forecasts: Drugs targeting beta-amyloid 74Key findings 74Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 3/13
  • 4. Find Industry reports, Company profilesReportLinker and Market StatisticsOverview for drugs targeting beta-amyloid 75Pipeline summary 75Beta-amyloid theory 77Better understand of the role of beta-amyloid is still required 78Passive immunotherapy and vaccines 80Secretase modulation 82Aggregation inhibition 83Comparative forecasts 83Bapineuzumab - passive immunotherapy 84Drug overview 84Drug profile 85SWOT analysis 85Clinical trial data 86Clinical outcome 87MRI measure of cerebral volume change 88Ongoing clinical trials 89Clinical attractiveness 89Patient potential 89Regular monitoring 90Commercial attractiveness 90Price of bapineuzumab and influencing factors 90Bapineuzumab market penetration 91Marketing resources and expertise unprecedented 91Competition in passive immunization 92Datamonitor drug assessment score card for bapineuzumab 92Satisfaction of unmet needs 94Forecasts to 2018 94Gammagard - passive immunotherapy 100Drug overview 100Drug profile 101SWOT analysis 101Clinical trial data 102Baxter Phase II clinical trial 102Other studies investigating the use of immunoglobulin in Alzheimers disease 103Ongoing Phase III clinical trial 104Clinical attractiveness 104Commercial attractiveness 104Competing immunoglobulin is in development 104Large scale production may represent a challenge 104Datamonitor drug assessment score card for Gammagard 105Satisfaction of unmet needs 106Forecasts to 2018 106Other drugs targeting beta-amyloid 110LY450139 - gamma secretase 110Drug overview 110Clinical trial data 111Ongoing clinical trials 112Datamonitors comment 113PBT2 - aggregation inhibition 114Drug overview 114Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 4/13
  • 5. Find Industry reports, Company profilesReportLinker and Market StatisticsClinical trial data 114Datamonitors comment 115LY2062430 - passive immunotherapy 116Drug overview 116Clinical trial data 116PF-04494700 - other beta-amyloid 117Drug overview 117Phase IIa clinical results 118Ongoing clinical trial program 119Posiphen - other beta-amyloid 119Drug overview 119Previous clinical trial failure with the negative enantiomer of phenserine 120Amyloid vaccines ACC-01 and CAD106 120ACC-001 121CAD106 121Good antibody response but no clinical efficacy signal 122Octagam - passive immunization 122Drug overview 122ELND005 - beta-amyloid aggregation inhibitor 123Drug overview 123ACI91 - beta-secretase inhibition 123Drug overview 123EHT0202 - alpha-secretase activator 124Drug overview 124NIC515 - gamma-secretase inhibitor 124Drug overview 124ARC029 - other beta-amyloid 124Drug overview 124PF4360365 - passive immunization 125Drug overview 125Late-stage development compounds recently discontinued 125Flurizan 125Alzhemed 1255. Pipeline Analysis & Forecasts: Drugs targeting tau hyperphosphorilation 126Key findings 126Overview for drugs targeting tau tangles 127Pipeline summary 127Rember - tau hyperphosphorylation inhibitor 127Drug overview 127Clinical trial data 128Datamonitors comments 130Patient potential 131Potential pricing 131Other drugs targeting tau tangles 131AL108 - tau hyperphosphorylation inhibitor 131NP-12 - Glycogen synthase kinase-3 beta inhibitor 133Drug overview 133GSK-3 beta hypothesis of Alzheimers disease 134Basic research identifies the GSK-3 beta target 134Preclinical in vivo analysis conducted with NP-12 134Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 5/13
  • 6. Find Industry reports, Company profilesReportLinker and Market StatisticsPhase I safety trial 135Ongoing Phase II clinical trial 135Datamonitors comment 1356. Pipeline Analysis & Forecasts: General neuroprotective drugs 137Key findings 137Overview for general neuroprotective drugs 138Pipeline summary 138Dimebon - MPTP, NMDA, cholinesterase inhibitor 138Drug overview 139Drug profile 139SWOT analysis 140Clinical trial data 140Estimation of disease modifying effects with Staggered Start and Natural History Staggered Start approach 142Preclinical animal studies suggest beta-amyloid modulation 143Ongoing clinical trials 144Clinical attractiveness 146Clinical significance of Dimebons various mechanisms of action yet to be established 146Inconvenient dosing regime 147Broad cognitive disorder patient potential 147Commercial attractiveness 148Potential for combination therapy with Aricept 148Pfizer partnership greatly expands the drugs commercial potential 148Lifecycle management planning 148Cost of Dimebon 149Datamonitor drug assessment score card for Dimebon 149Satisfaction of unmet needs 149Forecasts to 2018 150Other drugs with general neuroprotective characteristics 157Memryte - Gonadotrophin releasing hormone 157Drug overview 157Clinical trial data 158HF0220 - endogenous human steroid 158Drug overview 158Cogane - neurotrophic factor inducer 159Drug overview 159T817MA - neurotrophic agent 160Drug overview 1607. Pipeline Analysis & Forecasts: Symptomatic Relief 161Key findings 161Overview for drugs targeting symptomatic relief 162Pipeline summary 162Acetylcholinesterase inhibitors 163NMDA receptor antagonism 164Neuronal nicotinic receptor agonism 1655-HT6 receptor antagonist 165Other targets 165Comparative forecasts 165Aricept SR - acetylcholinesterase inhibitor 166Drug overview 166Drug profile 167Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 6/13
  • 7. Find Industry reports, Company profilesReportLinker and Market StatisticsSWOT analysis 167Clinical trial data 168Clinical attractiveness 168Commercial attractiveness 169Switching between brands 169Price for Aricept SR 170Datamonitor drug assessment score card for Aricept SR 170Satisfaction of unmet needs 170Forecasts to 2018 171Aricept patch - acetylcholinesterase inhibitor 175Drug overview 176Drug profile 176SWOT analysis 176Clinical trial data 177Clinical attractiveness 177Commercial attractiveness 178Price for Aricept patch 179Datamonitor drug assessment score card Aricept patch 179Satisfaction of unmet needs 180Forecasts to 2018 181Memantine extended-release -NMDA receptor antagonist 185Drug overview 186Drug profile 186SWOT analysis 186Clinical trial data 187Clinical attractiveness 188Commercial attractiveness 188Datamonitor drug assessment score card for memantine extended-release 189Satisfaction of unmet needs 189Forecasts to 2018 190Other drugs targeting symptomatic relief 193Huperzine A - acetylcholinesterase inhibitor 193Drug overview 193Clinical trial data 194Chinese clinical trial investigating the efficacy of Huperzine A 195Small-scale trial investigating the efficacy and safety of Huperzine A 196Mimopezil/Debio9902 SR - acetylcholinesterase inhibitor 196Drug overview 196Ongoing clinical trial program 197Ispronicline/AZD3480 - neuronal nicotinic receptor agonist 197Drug overview 197Clinical trial data 197Pozanicline/ABT-089 - neuronal nicotinic receptor agonist 198Drug overview 198R3487 - neuronal nicotinic receptor agonist 198Drug overview 198Clinical trial data 198Ongoing clinical trials 199EVP6124 - neuronal nicotinic receptor agonist 199Drug overview 199Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 7/13
  • 8. Find Industry reports, Company profilesReportLinker and Market StatisticsSAM-531 - 5-HT6 receptor antagonist 199Drug overview 199Ongoing clinical trials 199SB-742457 - 5-HT6 receptor antagonist 200Drug overview 200Clinical trial data 200Ongoing clinical trials 200PRX03140 - 5-HT4 receptor agonist 200Drug overview 200Clinical trial data 201Ongoing clinical trials 201CX717 - AMPA receptor agonist 201Drug overview 201MK-0249 202Drug overview 202Ongoing clinical trial program 2028. Innovative Early-Stage Approaches 203Key findings 203Delivery across the blood-brain barrier 204Carniotomy-based drug delivery 204EC Biodelivery, NSgene 204Molecular Trojan horse 205ArmaGens neurotrophin and AGT-160 205Tau immunotherapy 205The future of treatment in Alzheimers disease 206Prophylactic treatment 208Biomarkers significantly expand the patient population 209Structural imaging - MRI 210Functional imaging - PET and SPECT 210Radiotracer fluorodeoxyglucose 210Beta-amyloid radioligands using PET scans 211Tau neurofibrillary tangles 212Urine and serum biomarkers 212Bibliography 214Journals 214Web-site 218APPENDIX 224Methodology 224Datamonitor forecast methodology 224Contributing experts 224About Datamonitor 225About Datamonitor Healthcare 225About the Disease analysis team 225Datamonitor consulting 226Disclaimer 226List of TablesTable 1: Products in Phase II/III clinical development for Alzheimers disease, 2009 9Table 2: Sales forecasts ($m) for each pipeline drug, 2010-18 12Table 3: Elans Alzheimers disease late-stage pipeline, 2009 15Table 4: Pfizer/Wyeth Alzheimers disease late-stage pipeline, 2009 16Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 8/13
  • 9. Find Industry reports, Company profilesReportLinker and Market StatisticsTable 5: DIAG4 (ICD-10 derived) codes constituting >1% of total brand sales for drugs approved for Alzheimers disease, 2008 20Table 6: Dementia ICD-10 codes 22Table 7: Forms of dementia 23Table 8: Common clinical features in Alzheimers disease 24Table 9: Population size and prevalence rate of Alzheimers disease and other cognitive disorders across the seven majorpharmaceutical markets, 2009 29Table 10: Age-group trends in Alzheimers disease prevalence 31Table 11: Current and projected patient populations (millions) for cognitive disorders, 2008-18 35Table 12: Alzheimers disease prevalence and patient population comparison across the seven major pharmaceutical markets andBRIC countries, 2009 37Table 13: Projected Alzheimers disease population across the seven major pharmaceutical markets, the 5EU and the BRIC nations,2008-18 39Table 14: Leading treatments for Alzheimers disease, 2009 43Table 15: Total brand and indication-specific sales for drugs approved for Alzheimers disease, ($m), 2008 45Table 16: Percentage of total brand sales attributed to each indication group, 2004-08 47Table 17: Aricept (donepezil) - drug profile, 2009 48Table 18: Efficacy of acetylcholinesterase inhibitors as measured by change in ADAS-Cog above placebo 52Table 19: Head-to-head clinical trials of Aricept and other acetylcholinesterase inhibitors 53Table 20: Comparison of acetylcholinesterase inhibitor treatment response outcomes, according to a meta-analysis of clinical trials 60Table 21: Minimum acceptable product profile and target product profile 64Table 22: Typical Phase III clinical trial design in Alzheimers disease, 2009 67Table 23: Key products in late-stage R&D pipeline targeting beta-amyloid, 2009 76Table 24: Sales forecasts ($m) for beta-amyloid focused pipeline drugs across the seven major pharmaceutical markets, 2012-18 84Table 25: Bapineuzumab - drug profile, 2009 85Table 26: Bapineuzumab vs. the minimum acceptable product profile and target product profile 94Table 27: Impacting factors on the revenues of bapineuzumab, 2009-18 95Table 28: Bapineuzumab forecast methodology, US, 2012-18 96Table 29: Bapineuzumab forecast methodology, 5EU, 2012-18 97Table 30: Bapineuzumab forecast methodology, Japan, 2012-18 98Table 31: Bapineuzumab forecast across the seven major markets ($m), 2012-18 99Table 32: Gammagard - drug profile, 2009 101Table 33: Gammagard vs. minimum acceptable product profile and target product profile 106Table 34: Gammagard forecast methodology, US, 2012-18 107Table 35: Gammagard forecast methodology, 5EU, 2012-18 108Table 36: Gammagard forecast methodology, Japan, 2012-18 109Table 37: Gammagard forecast across the seven major markets ($m), 2012-18 110Table 38: Ongoing LY450139 clinical trials 113Table 39: Key products in late-stage R&D pipeline targeting tau tangles, 2009 127Table 40: Clinical trial results for high dose of AL-108 (15mg twice a day) in mild cognitive impairment subjects 133Table 41: Key products in late-stage R&D pipeline with a general neuroprotective mechanism, 2009 138Table 42: Dimebon - drug profile, 2009 139Table 43: Mean change from baseline on the ADAS-Cog at weeks 12 and 26 in the intention-to-treat population 141Table 44: Estimates from Dimebon Staggered Start and NHSS 143Table 45: Ongoing Dimebon clinical trials, 2009 145Table 46: Dimebon vs. the minimum acceptable product profile and target product profile 150Table 47: Dimebon forecast methodology, US, 2012-18 151Table 48: Dimebon forecast methodology, 5EU, 2012-18 153Table 49: Dimebon forecast methodology, Japan, 2012-18 155Table 50: Dimebon forecast across the seven major markets ($m), 2012-18 157Table 51: Key products in late-stage R&D pipeline providing symptomatic relief, 2009 163Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 9/13
  • 10. Find Industry reports, Company profilesReportLinker and Market StatisticsTable 52: Sales forecasts for pipeline symptomatic treatments across the seven major pharmaceutical markets, ($m), 2010-18 166Table 53: Aricept SR (donepezil sustained release) - drug profile, 2009 167Table 54: Aricept SR vs. the minimum acceptable product profile and target product profile 171Table 55: Aricept SR forecast methodology, US, 2010-18 172Table 56: Aricept SR forecast methodology, 5EU, 2011-18 173Table 57: Aricept SR forecast methodology, Japan, 2012-18 174Table 58: Aricept SR forecast across the seven major markets, 2010-18 175Table 59: Aricept patch - drug profile, 2009 176Table 60: Aricept patch vs. the minimum acceptable product profile and target product profile 181Table 61: Aricept patch forecast methodology, US, 2010-18 182Table 62: Aricept patch forecast methodology, 5EU, 2010-18 183Table 63: Aricept patch forecast methodology, Japan, 2012-18 184Table 64: Aricept patch forecast across the seven major markets, 2010-18 185Table 65: Memantine extended release - drug profile, 2009 186Table 66: Memantine extended-release vs. the minimum acceptable product profile and target product profile 190Table 67: Memantine extended-release forecast methodology, US, 2010-18 191Table 68: Memantine extended-release forecast methodology, 5EU, 2010-18 192Table 69: Memantine extended-release forecast across the seven major markets, 2010-18 193Table 70: Tracers for beta-amyloid plaques and other hallmarks of Alzheimers disease 212Table 71: Example of alternative tests to cerebrospinal fluid biomarkers in neurological conditions 213List of FiguresFigure 1: Late-stage pipeline Alzheimers disease drugs by class, 2009 11Figure 2: Datamonitor Pipeline Assessment Summary for Alzheimers disease, 2009 13Figure 3: Companies with more than one late-stage product in development of Alzheimers disease, 2009 14Figure 4: Potential relation between symptom classification and outcomes in mild cognitive impairment patients 27Figure 5: Prevalence of mild cognitive impairment (MCI) symptom and outcome subtypes 28Figure 6: Patient population estimates derived from different US Alzheimers disease estimates, 2009 32Figure 7: Projected patient population for all cognitive disorders across the seven major markets, 2005-18 33Figure 8: Demographic changes in the general US population, 2005-18 34Figure 9: Alzheimers disease patient population across the seven major pharmaceutical markets and BRIC nations, 2005-18 38Figure 10: Percentage change in elderly population (65 years and older), 2009-18 40Figure 11: Percentage of total brand sales Aricept, Namenda, Exelon and Razadyne (inc ER version sales) for Alzheimers disease,other dementia, and mild cognitive impairment across the seven major markets, 2008 46Figure 12: Alzheimers disease-specific sales revenue generated by Aricept across the seven major pharmaceutical markets, ($m),2009 49Figure 13: Percentage of total Aricept brand sales for each indication group, 2004-08 50Figure 14: Regional distribution of global Alzheimers disease-specific sales for the four drugs approved for Alzheimers disease, 200854Figure 15: Alzheimers disease-specific sales revenue across the seven major markets, ($m), 2004-08 55Figure 16: Percentage of total brand sales for each indication group, 2004-08 55Figure 17: Unmet need in Alzheimers disease treatment, 2009 56Figure 18: Cognitive decline of untreated Alzheimers disease patients and patients treated with a symptomatic drug 57Figure 19: Alzheimers disease symptom progression in the presence of a disease slowing therapy 58Figure 20: Alzheimers disease symptom progression in the presence of a disease modifying treatment administered at an early stageof the disease due to better diagnostic tools 59Figure 21: Alzheimers disease symptom progression in the presence of a disease modifying treatment administered at an early stageof the disease due to better diagnostic tools 62Figure 22: Clinical trial designs proposed to determine disease modification 70Figure 23: Amyloidogenic pathway: formation of toxic beta-amyloid 78Figure 24: Proposed passive immunization mechanism of action in Alzheimers disease 82Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 10/13
  • 11. Find Industry reports, Company profilesReportLinker and Market StatisticsFigure 25: SWOT analysis for bapineuzumab, 2009 86Figure 26: Bapineuzumab Phase II clinical trial design and results 87Figure 27: Datamonitors competitive positioning analysis of bapineuzumab in Alzheimers disease, 2009 93Figure 28: Sales forecasts for bapineuzumab in the seven major markets ($m), 2010-18 99Figure 29: SWOT analysis for Gammagard, 2009 102Figure 30: Datamonitors competitive positioning analysis of Gammagard in Alzheimers disease, 2009 105Figure 31: Sales forecasts for Gammagard (immunoglobulin) in the seven major markets ($m, 2012-18 110Figure 32: LY450139 Phase II clinical trial design and results 111Figure 33: SWOT analysis forDimebon, 2009 140Figure 34: Datamonitors competitive positioning analysis of Dimebon in Alzheimers disease, 2009 149Figure 35: Sales forecasts for Dimebon in the seven major markets ($m), 2012-18 156Figure 36: SWOT analysis for Aricept SR, 2009 168Figure 37: Datamonitors competitive positioning analysis of Aricept SR in Alzheimers disease, 2009 170Figure 38: Sales forecasts for Aricept SR in the seven major markets, ($m), 2010-18 175Figure 39: SWOT analysis for Aricept patch, 2009 177Figure 40: Percentage of total sales for Exelon oral and Exelon patch in the US, 2008 179Figure 41: Datamonitors competitive positioning analysis of Aricept patch in Alzheimers disease, 2009 180Figure 42: Sales forecasts for Aricept patch in the seven major markets. 2010-18 ($m) 185Figure 43: SWOT analysis for memantine extended-release, 2009 187Figure 44: Efficacy of memantine extended-release in moderate-to-severe Alzheimers disease 188Figure 45: Datamonitors competitive positioning analysis of memantine extended-release in Alzheimers disease, 2009 189Figure 46: Sales forecasts for memantine extended-release in the seven major markets. 2010-18 ($m) 193Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 11/13
  • 12. Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Product Formats Please select the product formats and the quantity you require. Digital Copy--USD 11 400.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 12/13
  • 13. Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Pipeline Insight: Alzheimers Disease - The ultimate high-risk, high-reward therapy market Page 13/13

×